{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:19:29Z","timestamp":1791267569002,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["NCT02149004"],"award-info":[{"award-number":["NCT02149004"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Safety and tolerability of analytical treatment interruptions (ATIs) as a vital part of human immunodeficiency virus type 1 (HIV-1) cure studies are discussed. We analyzed current evidence for the occurrence of adverse events (AEs) during TIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Our analysis included studies that reported on AEs in HIV-1\u2013infected patients undergoing TIs. All interventional and observational studies were reviewed, and results were extracted based on predefined criteria. The proportion of AEs was pooled using random-effects models. Metaregression was used to explore the influence of baseline CD4+ T-cell count, viral load, study type, previous time on combined antiretroviral therapy, and follow-up interval during TIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 1048 studies, of which 22 studies including 7104 individuals fulfilled the defined selection criteria. Included studies had sample sizes between 6 and 5472 participants, with durations of TI cycles ranging from 7 days to 27 months. The intervals of HIV-1-RNA testing varied from 2 days to 3 months during TIs. The overall proportion of AEs during TIs &amp;gt;4 weeks was 3% (95% confidence interval [CI], 0%\u20137%) and was lower in studies with follow-up intervals \u226414 days (0%; 95% CI, 0%\u20131%) than in studies with wider follow-up intervals (6%; 95% CI, 2%\u201313%; P value for interaction = .01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found moderate-quality evidence indicating that studies with narrow follow-up intervals did not show a substantial increase in AEs during TIs. Our findings indicate that ATI may be a safe strategy as part of HIV-1 cure trials by closely monitoring for HIV-1 rebound.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz417","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T19:14:10Z","timestamp":1558120450000},"page":"1406-1417","source":"Crossref","is-referenced-by-count":17,"title":["Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1\u2013infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials"],"prefix":"10.1093","volume":"70","author":[{"given":"Melanie","family":"Stecher","sequence":"first","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Cla\u00dfen","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"},{"name":"Laboratory of Experimental Immunology, Institute of Virology"},{"name":"Center for Molecular Medicine Cologne, University of Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"},{"name":"Laboratory of Experimental Immunology, Institute of Virology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Platten","sequence":"additional","affiliation":[{"name":"Labor Dr. Wisplinghoff , Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"Praxis am Ebertplatz , Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Behrens","sequence":"additional","affiliation":[{"name":"Department for Clinical Immunology and Rheumatology Hannover Medical School"},{"name":"German Center for Infection Research , Partner Site Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg Janne","family":"Vehreschild","sequence":"additional","affiliation":[{"name":"Department I for Internal Medicine, University Hospital of Cologne"},{"name":"German Center for Infection Research , Partner Site Bonn-Cologne"},{"name":"Medical Department II, University Hospital of Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,18]]},"reference":[{"key":"2024111411411127700_CIT0001","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"2024111411411127700_CIT0002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(13)70692-3","article-title":"Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024111411411127700_CIT0003","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev.immunol.18.1.665","article-title":"Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy","volume":"18","author":"Pierson","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"2024111411411127700_CIT0004","doi-asserted-by":"crossref","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","article-title":"Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals","volume":"14","author":"Clarridge","year":"2018","journal-title":"PLoS Pathog"},{"key":"2024111411411127700_CIT0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31813e62e1","article-title":"Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study","volume":"46","author":"Palmisano","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411127700_CIT0006","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(06)68887-9","article-title":"CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial","volume":"367","author":"Danel","year":"2006","journal-title":"Lancet"},{"key":"2024111411411127700_CIT0007","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count\u2013guided interruption of antiretroviral treatment","volume":"355","author":"The Strategies for Management of Antiretroviral Therapy (SMART) Study-Group","year":"2006","journal-title":"N Engl J Med"},{"key":"2024111411411127700_CIT0008","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2024111411411127700_CIT0009","author":"Wells"},{"key":"2024111411411127700_CIT0010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2024111411411127700_CIT0011","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"Centers for Disease Control and Prevention","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"2024111411411127700_CIT0012","doi-asserted-by":"crossref","first-page":"13288","DOI":"10.1073\/pnas.221452198","article-title":"Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects","volume":"98","author":"Ortiz","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024111411411127700_CIT0013","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00002030-199904160-00008","article-title":"HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group","volume":"13","author":"Neumann","year":"1999","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0014","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00002030-200003100-00013","article-title":"Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression","volume":"14","author":"Ruiz","year":"2000","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1089\/088922202760265588","article-title":"Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice","volume":"18","author":"Chen","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024111411411127700_CIT0016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00002030-200402200-00010","article-title":"Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial","volume":"18","author":"Maggiolo","year":"2004","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0017","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1097\/00002030-199905280-00001","article-title":"Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy","volume":"13","author":"Harrigan","year":"1999","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0018","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/archinternmed.2012.2719","article-title":"Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion","volume":"172","author":"Lodi","year":"2012","journal-title":"Arch Intern Med"},{"key":"2024111411411127700_CIT0019","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.qai.0000219779.50668.e6","article-title":"The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse)","volume":"42","author":"Bloch","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411127700_CIT0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/QAD.0000000000000987","article-title":"Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir","volume":"30","author":"Calin","year":"2016","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/VFRX-6T7X-UQ2W-V0LK","article-title":"Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses","volume":"3","author":"Lori","year":"2002","journal-title":"HIV Clin Trials"},{"key":"2024111411411127700_CIT0022","doi-asserted-by":"crossref","first-page":"F79","DOI":"10.1097\/00002030-199907300-00002","article-title":"Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy","volume":"13","author":"Garc\u00eda","year":"1999","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0023","first-page":"287","article-title":"CD4 cell-monitored treatment interruption in patients with a CD4 cell count &gt; 500 \u00d7 106 cells\/l","volume":"19","author":"Mussini","year":"2005","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0024","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1371\/journal.pmed.0010064","article-title":"Randomized, controlled trial of therapy interruption in chronic HIV-1 infection","volume":"1","author":"Papasavvas","year":"2004","journal-title":"PloS Medicine"},{"key":"2024111411411127700_CIT0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAI.0b013e31802f83bc","article-title":"Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells\/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN)","volume":"44","author":"Pog\u00e1ny","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411127700_CIT0026","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1086\/376535","article-title":"Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters","volume":"188","author":"Dybul","year":"2003","journal-title":"J Infect Dis"},{"key":"2024111411411127700_CIT0027","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/QAD.0b013e32835844d9","article-title":"Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial","volume":"26","author":"Goujard","year":"2012","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3851\/IMP2249","article-title":"Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function","volume":"18","author":"Imaz","year":"2013","journal-title":"Antivir Ther"},{"key":"2024111411411127700_CIT0029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000182628.66713.31","article-title":"Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial","volume":"40","author":"Hoen","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024111411411127700_CIT0030","first-page":"2381","article-title":"CD4+ cell-count\u2013guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy","volume":"18","author":"Boschi","year":"2004","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0031","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/archinternmed.2012.2719","article-title":"Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion","volume":"172","author":"Lodi","year":"2012","journal-title":"Arch Intern Med"},{"key":"2024111411411127700_CIT0032","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/QAD.0b013e328347b5e2","article-title":"CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption","volume":"25","author":"Nemes","year":"2011","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0033","doi-asserted-by":"crossref","first-page":"F19","DOI":"10.1097\/00002030-200106150-00001","article-title":"HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection","volume":"15","author":"Ruiz","year":"2001","journal-title":"AIDS"},{"key":"2024111411411127700_CIT0034","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"2024111411411127700_CIT0035","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"2024111411411127700_CIT0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2055-6640(20)31148-1","article-title":"Recruitment and ethical considerations in HIV cure trials requiring treatment interruption","volume":"1","author":"Arnold","year":"2015","journal-title":"J Virus Erad"},{"key":"2024111411411127700_CIT0037","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2352-3018(15)00248-9","article-title":"Ethics of ART interruption after stem-cell transplantation","volume":"3","author":"Sugarman","year":"2016","journal-title":"Lancet HIV"},{"key":"2024111411411127700_CIT0038","article-title":"Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens [abstract 593]","author":"Cambiano","year":"2014"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz417\/28968000\/ciz417.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1406\/32921212\/ciz417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1406\/32921212\/ciz417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:26:54Z","timestamp":1731587214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/7\/1406\/5491629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,18]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,5,18]]},"published-print":{"date-parts":[[2020,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz417","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,5,18]]}}}